This video brief features Dr. Nihar Desai reporting from AHA 2025 in New Orleans. He evaluates the real-world evidence demonstrating the impact of evolocumab on major adverse cardiovascular events (MACE) in patients with established atherosclerotic cardiovascular disease (ASCVD). Dr. Desai reviews the study design and population and highlights how these findings complement prior randomized trial data. Tune in to find out how evolocumab may contribute to cardiovascular risk reduction in routine clinical practice for patients with ASCVD.
Real-World Impact of Evolocumab on MACE Reduction in ASCVD

Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Provider(s)/Educational Partner(s)

Today’s healthcare environment is constantly evolving and advances of medical science occur at an accelerating pace. CME/CE plays an important role in the clinical environment and is an essential element of physician training, learning, and improvement, thereby importantly contributing to optimal patient care. Since 2000, MEDCON’s mission is to deliver high quality within the world of medical education by creating forums like PACE-CME, organizing live meetings, and providing online education. We aim to stimulate the review, exchange, and assimilation of key scientific findings to improve patients’ health, to raise awareness of new science underlying various disease states, and to accelerate the translation of this information into clinical practice.Commercial Support
This activity is supported by an independent educational grant from Amgen, Inc.
videoEvolocumab in Patients at High Cardiovascular Risk Without Prior MI or Stroke: Primary Results of the VESALIUS-CV Trial
Show more
videoGlobal Burden of Stroke and Myocardial Infarction in Patients at High Risk of First MACE: Insights From the VESALIUS-REAL Study
Show more
videoPrimary Results of the VESALIUS-CV Trial: Evolocumab in Patients at High Cardiovascular Risk Without Prior MI or Stroke
Show more
Overview
This video brief features Dr. Nihar Desai reporting from AHA 2025 in New Orleans. He evaluates the real-world evidence demonstrating the impact of evolocumab on major adverse cardiovascular events (MACE) in patients with established atherosclerotic cardiovascular disease (ASCVD). Dr. Desai reviews the study design and population and highlights how these findings complement prior randomized trial data. Tune in to find out how evolocumab may contribute to cardiovascular risk reduction in routine clinical practice for patients with ASCVD.
Provider(s)/Educational Partner(s)

Today’s healthcare environment is constantly evolving and advances of medical science occur at an accelerating pace. CME/CE plays an important role in the clinical environment and is an essential element of physician training, learning, and improvement, thereby importantly contributing to optimal patient care. Since 2000, MEDCON’s mission is to deliver high quality within the world of medical education by creating forums like PACE-CME, organizing live meetings, and providing online education. We aim to stimulate the review, exchange, and assimilation of key scientific findings to improve patients’ health, to raise awareness of new science underlying various disease states, and to accelerate the translation of this information into clinical practice.Commercial Support
This activity is supported by an independent educational grant from Amgen, Inc.
videoEvolocumab in Patients at High Cardiovascular Risk Without Prior MI or Stroke: Primary Results of the VESALIUS-CV Trial
Show more
videoGlobal Burden of Stroke and Myocardial Infarction in Patients at High Risk of First MACE: Insights From the VESALIUS-REAL Study
Show more
videoPrimary Results of the VESALIUS-CV Trial: Evolocumab in Patients at High Cardiovascular Risk Without Prior MI or Stroke
Show more
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?


